RxDoctor Payments Data

Steven Evans, DO

Occupational Medicine · Wyomissing, PANPI 1336149186

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Stryker at 33.0% of the total. 2025 is the largest year on record at $134, 3.2 times the $42 reported in 2019.

$347in general payments, 2019–2025

Across 16 payments — averaging $21.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$114
  • Collegium Pharmaceutical, Inc.$39
  • Kowa Pharmaceuticals America, Inc.$38
  • Vertex$34
  • Biodelivery Sciences International, Inc.$32
  • Boston Scientific$26
  • plus $64 from 4 others

What the payments were for

  • Food & beverage$347100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$347 in reported general payments places this provider in the 75th percentile of 35 occupational medicine providers in Pennsylvania.

See all occupational medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$170,561
Medicare patients
402
Services billed
1,928

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl70$55,492
Buprenorphine181$48,305
OxycontinOxycodone Hcl59$42,336
NucyntaTapentadol Hcl33$37,866
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen859$22,051
Morphine Sulfate ErMorphine Sulfate537$14,658
Fentanyl115$11,636
ButransBuprenorphine18$10,969
MovantikNaloxegol Oxalate12$8,981
Tramadol Hcl855$8,804
Gabapentin295$8,710
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen279$5,964
Lidocaine25$5,152
Tramadol Hcl-AcetaminophenTramadol Hcl/Acetaminophen177$3,557
Oxycodone Hcl133$2,517

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Nucynta$39$93,358103 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 35 occupational medicine providers in Pennsylvania.

Other occupational medicine in Wyomissing

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →